Novo Nordisk's amycretin, a long-acting GLP-1 and amylin receptor agonist, demonstrated significant weight loss and a tolerable safety profile in a Phase 1b/2a trial. The study tested both single and multiple ascending doses, with the highest dose cohort achieving substantial reductions in body weight over 36 weeks. Gastrointestinal issues were the most common side effects, but no unexpected safety concerns were reported.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.